The FHL2 regulation in the transcriptional circuitry of human cancers

Gene

Volumn 572, Issue 1, 2015, Pages 1-7

  Cao, Cyanne Ye ^a   Mok, Simon Wing Fai ^a   Cheng, Vincent Wing Sang ^a   Tsui, Stephen Kwok Wing ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bioinformatics; Breast cancer; Four and a half Lim (FHL2); Gastrointestinal cancer (GI cancer); Hepatocellular carcinoma (HCC); Liver cancer; Nucleus translocation; P53; Prostate cancer; Serum response factor (SRF); Specificity protein 1 (SP1); Transcriptional regulation

Indexed keywords

ACTIVATOR OF CREM IN TESTIS PROTEIN; CYSTEINE; FHL1 PROTEIN; FHL2 PROTEIN; FHL3 PROTEIN; FHL4 PROTEIN; HOMEODOMAIN PROTEIN; ONCOPROTEIN; PROTEIN P53; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; FHL2 PROTEIN, HUMAN; LIM HOMEODOMAIN PROTEIN; MUSCLE PROTEIN; SRF PROTEIN, HUMAN;

BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; HUMAN; LIVER CANCER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TRANSCRIPTION REGULATION; BIOLOGICAL MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; NEOPLASM; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE;

FEMALE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; LIM-HOMEODOMAIN PROTEINS; MALE; MODELS, BIOLOGICAL; MUSCLE PROTEINS; NEOPLASMS; PROTEIN INTERACTION MAPS; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84940608098     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.07.043     Document Type: Review

References (67)

1. Amaar Y.G., Thompson G.R., Linkhart T.A., Chen S.T., Baylink D.J., Mohan S. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J. Biol. Chem. 2002, 277:12053-12060.
2. Amann T., Egle Y., Bosserhoff A.K., Hellerbrand C. FHL2 suppresses growth and differentiation of the colon cancer cell line HT-29. Oncol. Rep. 2010, 23:1669-1674.
3. Arimura T., Hayashi T., Matsumoto Y., Shibata H., Hiroi S., Nakamura T., Inagaki N., Hinohara K., Takahashi M., Manatsu S.I., Sasaoka T., Izumi T., Bonne G., Schwartz K., Kimura A. Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 2007, 357:162-167.
4. Bach I. The LIM domain: regulation by association. Mech. Dev. 2000, 91:5-17.
5. Breen J.J., Agulnick A.D., Westphal H., Dawid I.B. Interactions between LIM domains and the LIM domain-binding protein Ldb1. J. Biol. Chem. 1998, 273:4712-4717.
6. Brown J.R., Nigh E., Lee R.J., Ye H., Thompson M.A., Saudou F., Pestell R.G., Greenberg M.E. Fos family members induce cell cycle entry by activating cyclin D1. Mol. Cell. Biol. 1998, 18:5609-5619.
7. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., Sevillano M., Nadal C., Jung P., Zhang X.H., Byrom D., Riera A., Rossell D., Mangues R., Massague J., Sancho E., Batlle E. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22:571-584.
8. Chan K.K., Tsui S.K., Lee S.M., Luk S.C., Liew C.C., Fung K.P., Waye M.M., Lee C.Y. Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 1998, 210:345-350.
9. Chan K.K., Tsui S.K., Ngai S.M., Lee S.M., Kotaka M., Waye M.M., Lee C.Y., Fung K.P. Protein-protein interaction of FHL2, a LIM domain protein preferentially expressed in human heart, with hCDC47. J. Cell. Biochem. 2000, 76:499-508.
10. Chartier N.T., Laine M., Gout S., Pawlak G., Marie C.A., Matos P., Block M.R., Jacquier-Sarlin M.R. Laminin-5-integrin interaction signals through PI 3-kinase and Rac1b to promote assembly of adherens junctions in HT-29 cells. J. Cell Sci. 2006, 119:31-46.
11. Chen D., Xu W., Bales E., Colmenares C., Conacci-Sorrell M., Ishii S., Stavnezer E., Campisi J., Fisher D.E., Ben-Ze'ev A., Medrano E.E. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res. 2003, 63:6626-6634.
12. Chen Y.H., Wu Z.Q., Zhao Y.L., Si Y.L., Guo M.Z., Han W.D. FHL2 inhibits the Id3-promoted proliferation and invasive growth of human MCF-7 breast cancer cells. Chin. Med. J. (Engl) 2012, 125:2329-2333.
13. Culig Z., Comuzzi B., Steiner H., Bartsch G., Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92:265-271.
14. El Mourabit H., Muller S., Tunggal L., Paulsson M., Aumailley M. Characterization of recombinant and natural forms of the human LIM domain-containing protein FHL2. Protein Expr. Purif. 2003, 32:95-103.
15. Fimia G.M., De Cesare D., Sassone-Corsi P. A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol. Cell. Biol. 2000, 20:8613-8622.
16. Frank D., Kuhn C., Katus H.A., Frey N. The sarcomeric Z-disc: a nodal point in signalling and disease. J. Mol. Med. (Berl) 2006, 84:446-468.
17. Gabriel B., Mildenberger S., Weisser C.W., Metzger E., Gitsch G., Schule R., Muller J.M. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res. 2004, 24:921-927.
18. Gabriel B., Fischer D.C., Orlowska-Volk M., zur Hausen A., Schule R., Muller J.M., Hasenburg A. Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study. J. Soc. Gynecol. Investig. 2006, 13:69-75.
19. Genini M., Schwalbe P., Scholl F.A., Remppis A., Mattei M.G., Schafer B.W. Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol. 1997, 16:433-442.
20. Gullotti L., Czerwitzki J., Kirfel J., Propping P., Rahner N., Steinke V., Kahl P., Engel C., Schule R., Buettner R., Friedrichs N. FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancer. Lab. Investig. 2011, 91:1695-1705.
21. Guo Z., Zhang W., Xia G., Niu L., Zhang Y., Wang X., Zhang Y., Jiang B., Wang J. Sp1 upregulates the four and half lim 2 (FHL2) expression in gastrointestinal cancers through transcription regulation. Mol. Carcinog. 2010, 49:826-836.
22. Heemers H.V., Regan K.M., Dehm S.M., Tindall D.J. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res. 2007, 67:10592-10599.
23. Heemers H.V., Regan K.M., Schmidt L.J., Anderson S.K., Ballman K.V., Tindall D.J. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol. 2009, 23:572-583.
24. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
25. Johannessen M., Moller S., Hansen T., Moens U., Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell. Mol. Life Sci. 2006, 63:268-284.
26. Joos H., Albrecht W., Laufer S., Reichel H., Brenner R.E. IL-1beta regulates FHL2 and other cytoskeleton-related genes in human chondrocytes. Mol. Med. 2008, 14:150-159.
27. Kadrmas J.L., Beckerle M.C. The LIM domain: from the cytoskeleton to the nucleus. Nat. Rev. Mol. Cell Biol. 2004, 5:920-931.
28. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., Schule R., Buettner R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66:11341-11347.
29. Kinoshita M., Nakagawa T., Shimizu A., Katsuoka Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int. J. Urol. 2005, 12:390-397.
30. Kleiber K., Strebhardt K., Martin B.T. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res. 2007, 27:55-61.
31. Kollara A., Brown T.J. Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. J. Steroid Biochem. Mol. Biol. 2010, 118:51-58.
32. Kurakula K., Sommer D., Sokolovic M., Moerland P.D., Scheij S., van Loenen P.B., Koenis D.S., Zelcer N., van Tiel C.M., de Vries C.J. LIM-only protein FHL2 is a positive regulator of liver X receptors in smooth muscle cells involved in lipid homeostasis. Mol. Cell. Biol. 2015, 35:52-62.
33. Martin B., Schneider R., Janetzky S., Waibler Z., Pandur P., Kuhl M., Behrens J., von der Mark K., Starzinski-Powitz A., Wixler V. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J. Cell Biol. 2002, 159:113-122.
34. Martin B.T., Kleiber K., Wixler V., Raab M., Zimmer B., Kaufmann M., Strebhardt K. FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 2007, 6:1779-1788.
35. McGrath M.J., Binge L.C., Sriratana A., Wang H., Robinson P.A., Pook D., Fedele C.G., Brown S., Dyson J.M., Cottle D.L., Cowling B.S., Niranjan B., Risbridger G.P., Mitchell C.A. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. Cancer Res. 2013, 73:5066-5079.
36. Meng X., Franklin D.A., Dong J., Zhang Y. MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 2014, 74:7161-7167.
37. Miano J.M. Serum response factor: toggling between disparate programs of gene expression. J. Mol. Cell. Cardiol. 2003, 35:577-593.
38. Morgan M.J., Madgwick A.J. The fourth member of the FHL family of LIM proteins is expressed exclusively in the testis. Biochem. Biophys. Res. Commun. 1999, 255:251-255.
39. Morlon A., Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3977-3982.
40. Ng E.K., Chan K.K., Wong C.H., Tsui S.K., Ngai S.M., Lee S.M., Kotaka M., Lee C.Y., Waye M.M., Fung K.P. Interaction of the heart-specific LIM domain protein, FHL2, with DNA-binding nuclear protein, hNP220. J. Cell. Biochem. 2002, 84:556-566.
41. Ng C.F., Ng P.K., Lui V.W., Li J., Chan J.Y., Fung K.P., Ng Y.K., Lai P.B., Tsui S.K. FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells. Cancer Lett. 2011, 304:97-106.
42. Ng C.F., Zhou W.J., Ng P.K., Li M.S., Ng Y.K., Lai P.B., Tsui S.K. Characterization of human FHL2 transcript variants and gene expression regulation in hepatocellular carcinoma. Gene 2011, 481:41-47.
43. Ng C.F., Xu J.Y., Li M.S., Tsui S.K. Identification of FHL2-regulated genes in liver by microarray and bioinformatics analysis. J. Cell. Biochem. 2014, 115:744-753.
44. Philippar U., Schratt G., Dieterich C., Muller J.M., Galgoczy P., Engel F.B., Keating M.T., Gertler F., Schule R., Vingron M., Nordheim A. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol. Cell 2004, 16:867-880.
45. Purcell N.H., Darwis D., Bueno O.F., Muller J.M., Schule R., Molkentin J.D. Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol. Cell. Biol. 2004, 24:1081-1095.
46. Putnik M., Zhao C., Gustafsson J.A., Dahlman-Wright K. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2012, 426:26-32.
47. Rokavec M., Li H., Jiang L., Hermeking H. The p53/microRNA connection in gastrointestinal cancer. Clin. Exp. Gastroenterol. 2014, 7:395-413.
48. Saeki Y., Endo T., Ide K., Nagashima T., Yumoto N., Toyoda T., Suzuki H., Hayashizaki Y., Sakaki Y., Okada-Hatakeyama M. Ligand-specific sequential regulation of transcription factors for differentiation of MCF-7 cells. BMC Genomics 2009, 10:545.
49. Samson T., Smyth N., Janetzky S., Wendler O., Muller J.M., Schule R., von der Mark H., von der Mark K., Wixler V. The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor. J. Biol. Chem. 2004, 279:28641-28652.
50. Schafer K., Neuhaus P., Kruse J., Braun T. The homeobox gene Lbx1 specifies a subpopulation of cardiac neural crest necessary for normal heart development. Circ. Res. 2003, 92:73-80.
51. Schmeichel K.L., Beckerle M.C. The LIM domain is a modular protein-binding interface. Cell 1994, 79:211-219.
52. Schmidt L.J., Duncan K., Yadav N., Regan K.M., Verone A.R., Lohse C.M., Pop E.A., Attwood K., Wilding G., Mohler J.L., Sebo T.J., Tindall D.J., Heemers H.V. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol. Endocrinol. 2012, 26:716-735.
53. Scholl F.A., McLoughlin P., Ehler E., de Giovanni C., Schafer B.W. DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J. Cell Biol. 2000, 151:495-506.
54. Tanahashi H., Tabira T. Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum. Mol. Genet. 2000, 9:2281-2289.
55. Treisman R. Journey to the surface of the cell: Fos regulation and the SRE. EMBO J. 1995, 14:4905-4913.
56. Turley E.A., Veiseh M., Radisky D.C., Bissell M.J. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression?. Nat. Clin. Pract. Oncol. 2008, 5:280-290.
57. Uchio E.M., Aslan M., Wells C.K., Calderone J., Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch. Intern. Med. 2010, 170:1390-1395.
58. van Zijl F., Mair M., Csiszar A., Schneller D., Zulehner G., Huber H., Eferl R., Beug H., Dolznig H., Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009, 28:4022-4033.
59. Wang J., Yang Y., Xia H.H., Gu Q., Lin M.C., Jiang B., Peng Y., Li G., An X., Zhang Y., Zhuang Z., Zhang Z., Kung H.F., Wong B.C. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007, 132:1066-1076.
60. Way J.C., Chalfie M. mec-3, a homeobox-containing gene that specifies differentiation of the touch receptor neurons in C. elegans. Cell 1988, 54:5-16.
61. Westphal P., Mauch C., Florin A., Czerwitzki J., Olligschlager N., Wodtke C., Schule R., Buttner R., Friedrichs N. Enhanced FHL2 and TGF-beta1 expression is associated with invasive growth and poor survival in malignant melanomas. Am. J. Clin. Pathol. 2015, 143:248-256. (quiz 307).
62. Wu Y., Guo Z., Zhang D., Zhang W., Yan Q., Shi X., Zhang M., Zhao Y., Zhang Y., Jiang B., Cheng T., Bai Y., Wang J. A novel colon cancer gene therapy using rAAV mediated expression of human shRNA-FHL2. Int. J. Oncol. 2013, 43:1618-1626.
63. Xiong Z., Ding L., Sun J., Cao J., Lin J., Lu Z., Liu Y., Huang C., Ye Q. Synergistic repression of estrogen receptor transcriptional activity by FHL2 and Smad4 in breast cancer cells. IUBMB Life 2010, 62:669-676.
64. Xu J., Zhou J., Li M.S., Ng C.F., Ng Y.K., Lai P.B., Tsui S.K. Transcriptional regulation of the tumor suppressor FHL2 by p53 in human kidney and liver cells. PLoS One 2014, 9. (e99359).
65. Yan J., Zhu J., Zhong H., Lu Q., Huang C., Ye Q. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett. 2003, 553:183-189.
66. Zhang W., Jiang B., Guo Z., Sardet C., Zou B., Lam C.S., Li J., He M., Lan H.Y., Pang R., Hung I.F., Tan V.P., Wang J., Wong B.C. Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer. Carcinogenesis 2010, 31:1220-1229.
67. Zheng Q., Zhao Y. The diverse biofunctions of LIM domain proteins: determined by subcellular localization and protein-protein interaction. Biol. Cell. 2007, 99:489-502.